Ionis Pharmaceuticals, Inc. (IONS) Shares Bought by Teachers Advisors LLC
Teachers Advisors LLC increased its stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) by 14.4% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 150,656 shares of the company’s stock after purchasing an additional 19,000 shares during the period. Teachers Advisors LLC owned 0.12% of Ionis Pharmaceuticals worth $7,664,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Capital Counsel LLC NY raised its position in shares of Ionis Pharmaceuticals by 8.5% during the 2nd quarter. Capital Counsel LLC NY now owns 41,280 shares of the company’s stock worth $2,100,000 after purchasing an additional 3,250 shares during the last quarter. Capital Fund Management S.A. acquired a new position in shares of Ionis Pharmaceuticals during the 2nd quarter worth about $4,432,000. Alliancebernstein L.P. raised its position in shares of Ionis Pharmaceuticals by 2.4% during the 2nd quarter. Alliancebernstein L.P. now owns 73,287 shares of the company’s stock worth $3,728,000 after purchasing an additional 1,708 shares during the last quarter. Private Advisor Group LLC acquired a new position in shares of Ionis Pharmaceuticals during the 2nd quarter worth about $263,000. Finally, Schroder Investment Management Group acquired a new position in shares of Ionis Pharmaceuticals during the 2nd quarter worth about $401,000. Hedge funds and other institutional investors own 89.24% of the company’s stock.
Shares of Ionis Pharmaceuticals, Inc. (NASDAQ IONS) opened at 56.01 on Friday. The company’s 50-day moving average is $53.04 and its 200 day moving average is $48.86. The stock has a market cap of $6.97 billion, a PE ratio of 269.28 and a beta of 3.12. Ionis Pharmaceuticals, Inc. has a 52 week low of $24.58 and a 52 week high of $60.01.
Ionis Pharmaceuticals (NASDAQ:IONS) last announced its earnings results on Tuesday, August 8th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.03). The business had revenue of $104.15 million for the quarter, compared to analyst estimates of $93.29 million. Ionis Pharmaceuticals had a return on equity of 15.52% and a net margin of 5.25%. The business’s revenue was up 170.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.47) EPS. Analysts forecast that Ionis Pharmaceuticals, Inc. will post ($0.17) earnings per share for the current fiscal year.
In other news, major shareholder Ionis Pharmaceuticals Inc acquired 3,125,000 shares of the business’s stock in a transaction dated Wednesday, July 19th. The stock was acquired at an average price of $8.00 per share, with a total value of $25,000,000.00. Following the completion of the transaction, the insider now directly owns 28,884,540 shares in the company, valued at approximately $231,076,320. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Chairman Stanley T. Crooke sold 27,500 shares of the business’s stock in a transaction that occurred on Wednesday, October 4th. The shares were sold at an average price of $52.89, for a total transaction of $1,454,475.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 81,000 shares of company stock valued at $4,356,650. 1.86% of the stock is currently owned by company insiders.
Several research analysts recently weighed in on the stock. Needham & Company LLC restated a “buy” rating and set a $64.00 price target on shares of Ionis Pharmaceuticals in a research report on Sunday, September 17th. Stifel Nicolaus restated a “hold” rating on shares of Ionis Pharmaceuticals in a research report on Tuesday, September 12th. Barclays PLC assumed coverage on shares of Ionis Pharmaceuticals in a research report on Wednesday, September 6th. They set an “equal weight” rating and a $55.00 price target for the company. BMO Capital Markets restated an “outperform” rating and set a $62.00 price target (up previously from $59.56) on shares of Ionis Pharmaceuticals in a research report on Tuesday, July 25th. Finally, Sanford C. Bernstein assumed coverage on shares of Ionis Pharmaceuticals in a research report on Thursday, July 27th. They set a “market perform” rating and a $57.00 price target for the company. Three analysts have rated the stock with a sell rating, seven have issued a hold rating and six have given a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $49.11.
Ionis Pharmaceuticals Profile
Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.
Want to see what other hedge funds are holding IONS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ionis Pharmaceuticals, Inc. (NASDAQ:IONS).
Receive News & Ratings for Ionis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.